IL108042A - שימוש בנגזרי בנזותיאופין בהכנת תרופות להורדת רמות כולסטירול בסרום - Google Patents

שימוש בנגזרי בנזותיאופין בהכנת תרופות להורדת רמות כולסטירול בסרום

Info

Publication number
IL108042A
IL108042A IL108042A IL10804293A IL108042A IL 108042 A IL108042 A IL 108042A IL 108042 A IL108042 A IL 108042A IL 10804293 A IL10804293 A IL 10804293A IL 108042 A IL108042 A IL 108042A
Authority
IL
Israel
Prior art keywords
serum cholesterol
raloxifene
cholesterol levels
piperidino
alkanoyloxy
Prior art date
Application number
IL108042A
Other languages
English (en)
Other versions
IL108042A0 (en
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of IL108042A0 publication Critical patent/IL108042A0/xx
Publication of IL108042A publication Critical patent/IL108042A/he

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Bipolar Transistors (AREA)
  • Semiconductor Lasers (AREA)
IL108042A 1992-12-22 1993-12-16 שימוש בנגזרי בנזותיאופין בהכנת תרופות להורדת רמות כולסטירול בסרום IL108042A (he)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US99522292A 1992-12-22 1992-12-22

Publications (2)

Publication Number Publication Date
IL108042A0 IL108042A0 (en) 1994-04-12
IL108042A true IL108042A (he) 1998-01-04

Family

ID=25541537

Family Applications (1)

Application Number Title Priority Date Filing Date
IL108042A IL108042A (he) 1992-12-22 1993-12-16 שימוש בנגזרי בנזותיאופין בהכנת תרופות להורדת רמות כולסטירול בסרום

Country Status (28)

Country Link
US (1) US5464845A (he)
EP (2) EP0605193B1 (he)
JP (1) JP3197129B2 (he)
KR (1) KR100278946B1 (he)
CN (1) CN1043608C (he)
AT (1) ATE233559T1 (he)
AU (1) AU669235B2 (he)
BG (1) BG61524B1 (he)
BR (1) BR9305182A (he)
CA (1) CA2112017C (he)
CZ (1) CZ283863B6 (he)
DE (1) DE69332735T2 (he)
DK (1) DK0605193T3 (he)
ES (1) ES2193142T3 (he)
HU (1) HU223342B1 (he)
IL (1) IL108042A (he)
MY (1) MY109345A (he)
NO (1) NO304924B1 (he)
NZ (1) NZ250486A (he)
PH (1) PH30430A (he)
PL (1) PL177349B1 (he)
RO (1) RO113806B1 (he)
RU (1) RU2123335C1 (he)
SG (1) SG52696A1 (he)
SK (1) SK279271B6 (he)
TW (1) TW383306B (he)
YU (1) YU48918B (he)
ZA (1) ZA939427B (he)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE39049E1 (en) 1992-07-28 2006-03-28 Eli Lilly And Company Methods for inhibiting bone loss
USRE38968E1 (en) 1992-07-28 2006-02-07 Eli Lilly And Company Methods for inhibiting bone loss using 6-hydroxy-2-(4-hydroxyphenyl)-benzo[b]thien-3-yl-4-[2-(piperidin-1-yl) ethoxyphenylimethanone hydrochloride
TW366342B (en) * 1992-07-28 1999-08-11 Lilly Co Eli The use of 2-phenyl-3-aroylbenzothiophenes in inhibiting bone loss
US5482949A (en) * 1993-03-19 1996-01-09 Eli Lilly And Company Sulfonate derivatives of 3-aroylbenzo[b]thiophenes
US5482950A (en) * 1993-10-15 1996-01-09 Eli Lilly And Company Methods for lowering serum cholesterol
US6489355B2 (en) * 1993-12-01 2002-12-03 Eli Lilly And Company Methods of inhibiting the effects of amyloidogenic proteins
NZ270077A (en) * 1993-12-14 1996-04-26 Lilly Co Eli Aqueous complexes of benzothiophenes and cyclodextrins
US5441966A (en) * 1993-12-21 1995-08-15 Eli Lilly And Company Methods of inhibiting Turner's syndrome
TW427902B (en) * 1993-12-21 2001-04-01 Lilly Co Eli Pharmaceutical composition for inhibiting low-density lipoprotein (LDL) oxidation and atherosclerosis
US6417198B1 (en) 1993-12-21 2002-07-09 Eli Lilly And Company Methods of inhibiting CNS problems in post-menopausal women
US5478847A (en) * 1994-03-02 1995-12-26 Eli Lilly And Company Methods of use for inhibiting bone loss and lowering serum cholesterol
CO4410190A1 (es) 1994-09-19 1997-01-09 Lilly Co Eli 3-[4-(2-AMINOETOXI)-BENZOIL]-2-ARIL-6-HIDROXIBENZO [b] TIOFENO CRISTALINO
US5629425A (en) * 1994-09-19 1997-05-13 Eli Lilly And Company Haloalkyl hemisolvates of 6-hydroxy-2-(4-hydroxyphenyl)-3-[4-piperidinoethoxy)-benzoyl]benzo[b]thiophene
EP0895781A3 (en) * 1994-10-20 1999-07-07 Eli Lilly And Company Use of benzofurans, benzothiophenes or indoles for the manufacture of a medicament for the treatment of conditions associated with an excess of tachykinins
US6562862B1 (en) 1994-10-20 2003-05-13 Eli Lilly And Company Methods of inhibiting physiological conditions associated with an excess of neuropeptide Y
US5552412A (en) * 1995-01-09 1996-09-03 Pfizer Inc 5-substitued-6-cyclic-5,6,7,8-tetrahydronaphthalen2-ol compounds which are useful for treating osteoporosis
US5484808A (en) * 1995-02-09 1996-01-16 Eli Lilly And Company Methods of inhibiting cell-cell adhesion
WO1996032937A1 (en) * 1995-04-21 1996-10-24 Eli Lilly And Company Benzothiophenes with novel basic side chains
JPH11510479A (ja) * 1995-06-07 1999-09-14 ネオルックス コーポレイション タモキシフェン類似体による心臓血管疾病の予防及び治療
US5731328A (en) * 1995-10-10 1998-03-24 Eli Lilly And Company Methods of inhibiting plasminogen activator inhibitor 1
US5726168A (en) * 1995-10-12 1998-03-10 Eli Lilly And Company Lipophilic benzothiophenes
IL120266A (en) 1996-02-28 2005-05-17 Pfizer Use of estrogen antagonists and estrogen agonists in the preparation of medicaments for inhibiting pathological conditions
HN1996000101A (es) 1996-02-28 1997-06-26 Inc Pfizer Terapia combinada para la osteoporosis
TW442286B (en) * 1996-02-28 2001-06-23 Pfizer New therapeutic uses of estrogen agonists
EP0801066A1 (en) * 1996-03-12 1997-10-15 Eli Lilly And Company Heterocyclic substituted benzothiophenes and pharmaceutical compositions
US6008377A (en) * 1996-03-19 1999-12-28 Eli Lilly And Company Synthesis of 3-[4-(2-aminoethoxy)-benzoyl]-2-aryl-6-hydroxy-benzo[B]thiophenes
US6458811B1 (en) 1996-03-26 2002-10-01 Eli Lilly And Company Benzothiophenes formulations containing same and methods
US5811437A (en) * 1996-05-21 1998-09-22 Eli Lilly And Company Methods of increasing nitric oxide synthesis
US5747509A (en) * 1996-06-03 1998-05-05 Schering Aktiengesellschaft Method for lowering plasma levels of lipoprotein(a)
CA2206752A1 (en) * 1996-07-02 1998-01-02 George Joseph Cullinan Benzothiophene compounds, intermediates, processes, and methods of use
US5980938A (en) * 1996-07-15 1999-11-09 Eli Lilly And Company Effect of compounds that suppress induction of plasminogen activator inhibitor 1 (PAI-1)
CA2214072C (en) * 1996-08-29 2006-11-14 Eli Lilly And Company Benzo [b] thiophene compounds, intermediates, processes, compositions, and methods
US5773432A (en) * 1996-10-30 1998-06-30 Schering Aktiengesellschaft Method for lowering plasma levels of lipoprotein(a)
UA59384C2 (uk) 1996-12-20 2003-09-15 Пфайзер, Інк. Похідні сульфонамідів та амідів як агоністи простагландину, фармацевтична композиція та способи лікування на їх основі
EP0979076A4 (en) * 1997-04-30 2003-03-19 Lilly Co Eli INTERMEDIATES AND PROCESSES FOR THE PREPARATION OF BENZO b] THIOPHENES
CN1254280A (zh) * 1997-04-30 2000-05-24 伊莱利利公司 用于制备取代的苯并[b]噻吩的区域选择性烷基化方法
CA2236254A1 (en) * 1997-04-30 1998-10-30 David Warren Hoard Process for preparing benzo¬b|thiophenes
JP2001522372A (ja) * 1997-04-30 2001-11-13 イーライ・リリー・アンド・カンパニー ベンゾチオフェンの製造方法
AU7261598A (en) * 1997-04-30 1998-11-24 Eli Lilly And Company Intermediates and a process for preparing benzo{b}thiophenes
CA2231013A1 (en) * 1997-04-30 1998-10-30 Eli Lilly And Company Process for preparing benzoic acid derivative intermediates and benzothiophene pharmaceuticals
US6124314A (en) * 1997-10-10 2000-09-26 Pfizer Inc. Osteoporosis compounds
US6096781A (en) * 1997-11-14 2000-08-01 Eli Lilly And Company 2-arylbenzo[B]thiophenes useful for the treatment of estrogen deprivation syndrome
US7005428B1 (en) 1998-06-11 2006-02-28 Endorecherche, Inc. Medical uses of a selective estrogen receptor modulator in combination with sex steroid precursors
US6465445B1 (en) 1998-06-11 2002-10-15 Endorecherche, Inc. Medical uses of a selective estrogen receptor modulator in combination with sex steroid precursors
US6353003B1 (en) 1998-06-17 2002-03-05 Eli Lilly And Company Method for reducing levels of homocysteine and C-reactive protein
US6087378A (en) * 1998-10-13 2000-07-11 Eli Lilly And Company Pharmaceutical formulations and applications thereof for the treatment of estrogen deprivation syndrome
EA005293B1 (ru) 1999-12-22 2004-12-30 Пфайзер Продактс Инк. Производные пирролидин-2-она и их применение при лечении остеопороза
ATE346159T1 (de) * 2000-05-08 2006-12-15 Pfizer Prod Inc Enzymatische spaltung von selektiven modulatoren des östrogenrezeptors
US20030216358A1 (en) * 2001-07-05 2003-11-20 Muchmore Douglas Boyer Method for enhancing bone mineral density gain
US20060106010A1 (en) * 2003-05-27 2006-05-18 Black Larry J Methods for inhibiting bone loss
US20070191319A1 (en) * 2003-12-17 2007-08-16 Pfizer Inc. Treatment of conditions that present with low bone mass by continuous combination therapy with selective prostaglandin ep4 receptor agonists and an estrogen
CA2694642C (en) 2007-07-27 2017-05-16 Container Stuffers, Llc Cargo loader
CN101669557B (zh) * 2009-08-20 2012-07-25 杭州六易科技有限公司 一种清热解毒凉茶的制作方法
WO2016021706A1 (ja) * 2014-08-08 2016-02-11 カズマパートナーズ株式会社 縮合複素環化合物

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4133814A (en) * 1975-10-28 1979-01-09 Eli Lilly And Company 2-Phenyl-3-aroylbenzothiophenes useful as antifertility agents
US4418068A (en) * 1981-04-03 1983-11-29 Eli Lilly And Company Antiestrogenic and antiandrugenic benzothiophenes
US4729999A (en) * 1984-10-12 1988-03-08 Bcm Technologies Antiestrogen therapy for symptoms of estrogen deficiency
TW366342B (en) * 1992-07-28 1999-08-11 Lilly Co Eli The use of 2-phenyl-3-aroylbenzothiophenes in inhibiting bone loss
US5441964A (en) * 1993-10-15 1995-08-15 Eli Lilly And Company Methods for inhibiting bone loss using substituted benzothiophene

Also Published As

Publication number Publication date
CZ279093A3 (en) 1994-07-13
ATE233559T1 (de) 2003-03-15
CA2112017C (en) 2005-06-14
SG52696A1 (en) 1998-09-28
PL177349B1 (pl) 1999-10-29
MY109345A (en) 1997-01-31
NZ250486A (en) 1997-06-24
BG98317A (en) 1995-02-28
SK142193A3 (en) 1995-01-12
ES2193142T3 (es) 2003-11-01
JP3197129B2 (ja) 2001-08-13
EP0605193B1 (en) 2003-03-05
HUT69686A (en) 1995-09-28
NO934740D0 (no) 1993-12-21
NO934740L (no) 1994-06-23
PL301579A1 (en) 1994-06-27
HU9303676D0 (en) 1994-04-28
CN1094042A (zh) 1994-10-26
AU669235B2 (en) 1996-05-30
BR9305182A (pt) 1994-08-16
EP0605193A1 (en) 1994-07-06
DE69332735T2 (de) 2003-10-23
YU79893A (sh) 1997-05-28
RO113806B1 (ro) 1998-11-30
NO304924B1 (no) 1999-03-08
AU5257893A (en) 1994-07-07
KR940013501A (ko) 1994-07-15
DK0605193T3 (da) 2003-03-31
JPH06234632A (ja) 1994-08-23
SK279271B6 (sk) 1998-08-05
EP1238667A2 (en) 2002-09-11
EP1238667A3 (en) 2003-12-10
ZA939427B (en) 1995-06-15
CA2112017A1 (en) 1994-06-23
RU2123335C1 (ru) 1998-12-20
HU223342B1 (hu) 2004-06-28
IL108042A0 (en) 1994-04-12
PH30430A (en) 1997-05-09
CN1043608C (zh) 1999-06-16
YU48918B (sh) 2002-11-15
DE69332735D1 (de) 2003-04-10
KR100278946B1 (ko) 2001-01-15
TW383306B (en) 2000-03-01
CZ283863B6 (cs) 1998-06-17
BG61524B1 (bg) 1997-11-28
US5464845A (en) 1995-11-07

Similar Documents

Publication Publication Date Title
EP0605193B1 (en) Use of benzothiophenes for treatment of hypercholesterolaemia
CA2101356C (en) Improvements in or relating to benzothiophenes
US5455275A (en) Methods for inhibiting endometriosis and uterine fibroid disease with 1,1,2-triphenylbut-1-ene derivatives
PT652005E (pt) Metodo para inibicao da endometriose
US5446071A (en) Methods for lowering serum cholesterol
US5663184A (en) Methods of inhibiting CNS problems in post-menopausal women
US5426123A (en) Method for lowering serum cholesterol with 1,1,2-triphenylbut-1-ene derivatives
PT662325E (pt) Inibicao da disgenese do ovario, puberdade atrasada, ou infantilismo sexual
US6110942A (en) Method for minimizing the uterotrophic effect of droloxifene

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed
KB Patent renewed
MM9K Patent not in force due to non-payment of renewal fees